The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F17%3A43875627" target="_blank" >RIV/62157124:16370/17:43875627 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3109/10837450.2015.1089900" target="_blank" >http://dx.doi.org/10.3109/10837450.2015.1089900</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10837450.2015.1089900" target="_blank" >10.3109/10837450.2015.1089900</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin

Popis výsledku v původním jazyce

Context: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. Objective: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon (R) CL-F, Vivasol (R) and Explotab (R)). Materials and methods: LSS were prepared by spraying rosuvastatin solution onto Neusilin (R) US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. Results and discussion: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab (R) showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon (R) CL-F (&gt;= 2.5% w/w). Also tablets with Vivasol (R) (2.5-4.0% w/w) showed fast disintegration and complete drug release. Conclusion: Kollidon (R) CL-F and Vivasol (R) in concentration &gt;= 2.5% are suitable superdisintegrants for LSS with enhanced release of drug.

Název v anglickém jazyce

The effect of superdisintegrants on the properties and dissolution profiles of liquisolid tablets containing rosuvastatin

Popis výsledku anglicky

Context: The preparation of liquisolid systems (LSS) represents a promising method for enhancing a dissolution rate and bioavailability of poorly soluble drugs. The release of the drug from LSS tablets is affected by many factors, including the disintegration time. Objective: The evaluation of differences among LSS containing varying amounts and types of commercially used superdisintegrants (Kollidon (R) CL-F, Vivasol (R) and Explotab (R)). Materials and methods: LSS were prepared by spraying rosuvastatin solution onto Neusilin (R) US2 and further processing into tablets. Varying amounts of superdisintegrants were used and the differences among LSS were evaluated. The multiple scatter plot method was used to visualize the relationships within the obtained data. Results and discussion: All disintegrants do not showed negative effect on the flow properties of powder blends. The type and concentration of superdisintegrant had an impact on the disintegration time and dissolution profiles of tablets. Tablets with Explotab (R) showed the longest disintegration time and the smallest amount of released drug. Fastest disintegration and dissolution rate were observed in tablets containing Kollidon (R) CL-F (&gt;= 2.5% w/w). Also tablets with Vivasol (R) (2.5-4.0% w/w) showed fast disintegration and complete drug release. Conclusion: Kollidon (R) CL-F and Vivasol (R) in concentration &gt;= 2.5% are suitable superdisintegrants for LSS with enhanced release of drug.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmaceutical development and technology

ISSN

1083-7450

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

138-147

Kód UT WoS článku

000394648300003

EID výsledku v databázi Scopus

—